DOTmed Home MRI Oncology Ultrasound Molecular Imaging X-Ray Cardiology Health IT Business Affairs
News Home Parts & Service Operating Room CT Women's Health Proton Therapy Endoscopy HTMs Mobile Imaging
Aktueller Standort:
> This Story

Log in oder Register to rate this News Story
Forward Printable StoryPrint Comment



More Industry Headlines

AHRA 2018 product showcase Some of the products and services on display at the event

AHRA 2018 exhibitors A few of the companies you won't want to miss in Orlando

Study: CT use possibly linked to higher risk for brain tumors Exudes greater amounts of radiation than other modalities

Low-risk patients subject to costly, unnecessary breast imaging, says study Ranges from $2,000 to $8,000, creates high-deductible burdens

Lumitron to develop laser-based X-ray systems with higher image resolution than CT Image resolution 100 times better than CT, 1000 times better than X-ray

Secondary image interpretations on the rise, says study Increasing demand among clinicians, greater acceptance by payors

A look back at the history of mammography Robert Salomon's 1913 research showed there were different types of breast cancer

RCM: The untapped potential for lab valuation Challenges abound in the lab market

ECRI to fill guidance void left by shutdown of NGC website Launching interim website with clinical practice guidelines this fall

Israel grants $33 milion to GE, Medtronic, Change Healthcare to boost R&D Bringing high-quality jobs and biotech innovation to the country

Cancer treatments using immune system come with a cost

By Thom Wellington
From the February 2018 issue of DOTmed HealthCare Business News magazine

To many fighting cancer, palliative care is considered the ending point – just dealing with pain management until life ends.

Recent developments outside of normal cancer treatment have emerged with both promise and staggering treatment pricing. While chemotherapy is still considered a mainstay in fighting cancer, it has its drawbacks in the form of adverse side-effects. As more cancer cells grow in the patient’s body, they take over useful cell space. Chemotherapy drugs are designed to interfere with the cancer cell’s ability to divide and reproduce. Unfortunately, chemotherapy can also interfere with healthy cells, further weakening the patient’s immune system. To many, the treatments mean dealing with the pain and hoping things improve.

Story Continues Below Advertisement

Source-Ray, Inc. - Innovations In Portable X-Ray

SRI is a leading Developer, Manufacturer & Supplier of Innovative Portable Imaging Equipment. We offer Lightweight, Agile, Easy to Maneuver Portable X-Ray Systems ideal for maneuvering in tight spaces. Call us at 631-244-8200

Recent approvals from the Food and Drug Administration (FDA) have created controlled chaos with pharmaceutical development companies being purchased at sky-high multiples and drug treatment costs reaching stratospheric heights. Kite Pharma, the developer of an FDA-approved treatment which genetically alters a patient’s cells to actually attack cancer, fits both scenarios. The innovative treatment for aggressive non-Hodgkin’s lymphoma has seen strong positive results in all trials, and the company was recently purchased by Gilead Sciences for $11.9 billion. In addition, the treatment known as CAR T-cell therapy and branded as Yescarta has an eye-opening treatment price of $373,000.

Innovative cancer treatment is quickly developing. Immuno-oncology holds the promise of treating certain forms of cancer, such as prostate cancer and melanoma, by leveraging the power of the human immune system. The human immune system is our built-in natural defense mechanism which eliminates foreign substances, cells and tissues that attack our bodies. The practical application of this practice is just beginning to emerge. Immuno-oncology molecules are designed to help identify cancer cells and destroy them.

Gene therapy
Gene replacement therapy sounds invasive and significantly complex to most patients. In actuality, gene replacement is a simple concept: insert a copy of a specific gene into targeted cells. The process introduces genetic material into targeted cells to either produce a protein or to overcompensate for abnormal genes. The process is intended to place a normal gene to replace an abnormal gene, or to provide restoration of a malfunctioning protein.
  Pages: 1 - 2 - 3 >>


You Must Be Logged In To Post A Comment

Erhöhen Sie Ihren Bekanntheitsgrad
Auktionen + Privatverkäufe
Den besten Preis erzielen
Geräte/Geräteteile kaufen
Den günstigsten Preis finden
Daily News
Die neuesten Nachrichten lesen
Alle DOTmed Benutzer durchsuchen
Ethik auf DOTmed
Unseren Ethik-Standard anzeigen
Gold-Parts Verkäufer-Programm
PH-Anfragen erhalten
Gold Service Dealer-Programm
Anfragen empfangen
Alle Gesundheitsdienstleister-Tools anzeigen
Einen Job suchen
Parts Hunter +EasyPay
Angebote für Geräteteile erhalten
Kürzlich zertifiziert
Kürzlich zertifizierte Benutzer anzeigen
Kürzlich bewertet
Kürzlich zertifizierte Benutzer anzeigen
Rental Central
Geräte billiger mieten
Geräte/Geräteteile verkaufen
Das meiste Geld erhalten
Service-Techniker Forum
Hilfe und Beratung finden
Einfache Angebots-Anfrage
Angebote für Geräte erhalten
Virtuelle Messe
Service für Geräte finden
Access and use of this site is subject to the terms and conditions of our LEGAL NOTICE & PRIVACY NOTICE
Property of and Proprietary to, Inc. Copyright ©2001-2018, Inc.